Company intelligence / Profile preview
Engine Biosciences
- Ownership
- Private
- Employees
- ~40
- Development stage
- Preclinical
Overview
Engine Biosciences has built a robust preclinical pipeline anchored by over thirty novel precision medicine opportunities validated using its proprietary computational and experimental platforms. Its lead program targeting PKMYT1 has demonstrated strong preclinical proof-of-concept across multiple tumor models, with supporting clinical data for the target itself. The company continues to advance these programs toward the clinic while expanding its biomarker-driven discovery efforts.
- Therapeutic areas
- OncologyOther
- Modalities
- Small molecules (primary focus)Potential for other modalities via platform, but small molecules are most referenced
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Partnerships
Beyond the preview
Go deeper on Engine Biosciences.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Engine Biosciences.